Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Medifast first quarter net revenue increases 20% to $88.9 million

Medifast, Inc.a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

Mindray first quarter net revenues increase 21.1% to $219.0 million

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2012.

From Mindray 8 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Claraview reports successful deployment of Enterprise Data Integrity solution for Affinity Health Plan

Claraview, a division of Teradata, a strategy and technology consultancy focused exclusively on business intelligence (BI) and analytic solutions, announced today the successful deployment of the Enterprise Data Integrity (EDI) solution for Affinity Health Plan.

7 May 2012

ADVENTRX first quarter net loss increases to $4.2M

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

7 May 2012

Pro-Dex third quarter sales decrease 34% to $4.5 million

PRO-DEX, INC. today announced financial results for its fiscal third quarter and nine months ended March 31, 2012.

5 May 2012

Breckenridge finalizes agreement with Huahai to market Nevirapine Tablets

Breckenridge Pharmaceutical, Inc. announced today that it has finalized its agreement with Zhejiang Huahai Pharmaceuticals Co., Ltd. (Huahai) to market Nevirapine Tablets. Nevirapine 200mg Tablets are AB rated to Viramune a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS, which is marketed by Boehringer Ingelheim.

5 May 2012

Researchers develop new kind of hip implant

Hip replacement is one of the most frequent operations carried out in Germany. Each year, doctors implant some 200,000 artificial hip joints. Often the artificial hips need to be replaced just ten years later. In the future, a new implant currently being developed using high technology materials could help prevent premature revision surgeries.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Affymetrix total revenue decreases to $65.2 million

Affymetrix, Inc., today reported its operating results for the first quarter of 2012. Total revenue for the quarter was $65.2 million, as compared to total revenue of $73.7 million for the same period of 2011.

4 May 2012

FDA issues Complete Response Letter to Alexza’s ADASUVE NDA

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.

4 May 2012

Emergent BioSolutions first quarter total revenues increase to $50.3M

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2012.

4 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

CSI third quarter revenues increase 5% to $21.2 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2012.

3 May 2012

STAAR Surgical first quarter total revenue increases 4% to $15.5M

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product in the first quarter ended March 30, 2012 increased 25% to $8.6 million.

3 May 2012

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Xcellerex introduces XDUO Quad single-use mixing system for biomanufacturing

Xcellerex, Inc., a provider of turnkey biomanufacturing solutions, has launched its XDUO Quad single-use mixing system supporting single-use biomanufacturing in upstream and downstream mixing applications and unit operations.

3 May 2012

AtriCure first quarter revenue increases 11.8% to $17.5 million

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.

3 May 2012

ArthroCare first quarter total revenue increases 5.6% to $92.9 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the first quarter ended March 31, 2012.

3 May 2012

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, announced today that it has entered into a Development and License Agreement with Novo Nordisk A/S, a global healthcare company and leader in diabetes care.

From Novo Nordisk 2 May 2012